Supported by multidisciplinary care involving surgeons, endocrinologists, dietitians, and behavioral specialists
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with obesity: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial." The Lancet, vol
A clinical, histopathological and kinetic analysis
We will also highlight how a personalized approach, such as the one we offer at TrimRx, plays a pivotal role in achieving sustainable results
Remember that your healthcare provider's primary concern is your safety and long-term health, and their recommendations are based on current evidence and clinical guidelines
Sourris KC, Ding Y, Maxwell SS, Al-Sharea A, Kantharidis P, Mohan M, Rosado CJ, Penfold SA, Haase C, Xu Y, et al